Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.35 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1368786 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| SCHEMBL91524 | 0.97 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| SCHEMBL16837198 | 0.89 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| SCHEMBL21696261 | 0.89 | HTR6 (0.41) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| Hydrochloric Acid SCHEMBL2200285 | 0.82 | HTR6 (0.48) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| Hydrochloric Acid SCHEMBL2200278 | 0.82 | HTR6 (0.48) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| Hydrochloric Acid SCHEMBL38659074 | 0.82 | HTR6 (0.48) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| Hydrochloric Acid SCHEMBL21570154 | 0.82 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL1485035 | 0.79 | HTR6 (0.50) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 | |
| SCHEMBL6700639 | 0.79 | HTR6 (0.50) | SMN1; SMN2CYP2A13ALDH1A1HPGDHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325129-A1 | METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2020-10-15 | — | — | US | claimed |
| US-12583837-B2 | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4048279-B1 | 2-(2,6-DIOXOPIPERIDIN-3YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1. 3-DIONE FOR USE IN TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | CELGENE CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3952880-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE FOR USE IN THE TREATMENT OF NON-HODGKIN LYMPHOMA | CELGENE CORP (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4559911-A1 | NOVEL HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING THE SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-05-28 | — | — | EP | disclosed |
| US-20250144108-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2025-05-08 | — | — | US | disclosed |
| CN-119585265-A | Novel heterocyclic compound and pharmaceutical composition for inhibiting autotaxin comprising same | 株式会社次代生物科学 | 2025-03-07 | — | — | CN | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-9452986-B2 | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| WO-2015119998-A1 | 6-HETEROARYLOXY- AND 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND USES THEREOF | ABBVIE, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150218102-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2015-08-06 | — | — | US | disclosed |
| WO-2007136326-A2 | ) T E TEXT AS EEN ESTA S E Y T S UT O TY TO REA AS O OWS: 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 3 | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270399-A1 | New compounds 302 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | disclosed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | HTR6 3647/4885DPP4 4483/4885SMN1; SMN2 2625/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | HTR6 3647/4885DPP4 4483/4885SMN1; SMN2 2625/4885 |
| US-20070270399-A1 | New compounds 302 | CYP11B2, CYP11B1, CYP4B1 | HTR6 2798/4885DPP4 1115/4885SMN1; SMN2 3036/4885 |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | TNF, TNFRSF1A, CD40 | HTR6 1171/4885DPP4 1740/4885SMN1; SMN2 4370/4885 |
| US-20200325129-A1 | METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | MALT1, BCL6, MTX2 | HTR6 2032/4885DPP4 3820/4885SMN1; SMN2 3205/4885 |
| US-20250144108-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AND METHODS OF USING THE SAME | MTX2, MDN1, MTX1 | HTR6 1268/4885DPP4 2439/4885SMN1; SMN2 419/4885 |
| US-12583837-B2 | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising and methods of using the same | MEF2D, MAP2, MYADM | HTR6 3390/4885DPP4 4043/4885SMN1; SMN2 61/4885 |
| US-20150218102-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | HTR6 454/4885DPP4 2136/4885SMN1; SMN2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.